Last year, the top winners at the prestigious Pharma Lions event at Cannes were not in fact pharma companies, and in 2023 that trend continues as a digital face-tracking app, a breast cancer inequality campaign and the sounds of dying cancer cells take the top prizes.
SK Biopharmaceuticals, Co., Ltd., today announced that it has entered into a licensing agreement for Eurofarma, a Brazilian pharmaceutical company...
PARSIPPANY, N.J., June 22, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has entered into a distribution agreement with Eurofarma Laboratories S.A. (Eurofarma) for the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in Latin America.
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA (‘Eurofarma’). The $1.0 million milestone payment was triggered by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection (‘CDI’).
Japan’s Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said.
Eisai Co., Ltd. has entered into an agreement with Eurofarma Laboratorios, to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride in 17 countries, in Latin America and the Caribbean, excluding Brazil,
Check out the new generics approved for commercialization in Brazil
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Eurofarma Laboratórios has submitted a marketing authorization application for delafloxacin (marketed under the trade name Baxdela™ in the U.S.) in Argentina with the Ministry of Health'sNational Administration of Drugs, Foods and Medical Technology (ANMAT). Eurofarma Laboratórios is Melinta’s commercialization and distribution partner for all countries in South and Central America and the Caribbean, including Argentina. The proposed indication for delafloxacin in Argentina is for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).
EuroPharma.DK ApS Fails EDQM Inspection